Progress of immune status in systemic lupus erythematosus
- Author:
- No author available
- Journal Title:
- International Journal of Pediatrics
- Issue:
- 4
- DOI:
- 10.3760/cma.j.issn.1673-4408.2012.04.020
- Key Word:
- 系统性红斑狼疮;淋巴细胞亚群;免疫紊乱;Systemic lupus erythematosus;Lymphocyte subsets;Immunologic derangement
Abstract： Systemic lupus erythematosus is an autoimmune-mediated inflammatory diseases in which immunologic derangement throughout this process.There are a varriety of abnormal immunoregulation,including the disturbance of Help T cell 1,Help T cell 2,Th17 cell and regulatory T cell( Treg cell),disfunction of the B cell subsets and deficiency of the immune tolerance,lead to the disturbance of related cytokines.Recently,it was indicated that the abnormal of cross regulation existencd between Help T cell 1 and Th17 cell,and the disfunction of non-antibody-dependent B cells may play an important role in the pathogenesis of SLE,According to different immune status,appropriate and targeted treatment was given in order to improve the prognosis of the patients with systemic lupus erythematosus.
- [1]王晓,舒强,李栋,等.系统性红斑狼疮初发患者外周血T细胞免疫球蛋白及黏蛋白域蛋白-3及其配体半乳糖凝集素-9表达水平和意义[J].2011,(4).
- [2]曾华松.小儿系统性红斑狼疮诊断及治疗[J].2006,(6).
- [3]王敏.Th17细胞研究进展[J].2011,(2).
- [4]何德宁,董光富.B细胞在系统性红斑狼疮发病机制中的作用研究进展[J].2011,(2).
- [5]石琳熙,柳爱华,宝福凯.Th17细胞及其与感染性疾病关系的研究进展[J].2011,(3).
- [6]Ismael, Calero,I?aki, Sanz.Targeting B cells for the treatment of SLE: the beginning of the end or the end of the beginning?[J].2010,10(54).
- [7]Mangini AJ,van-Seventer GA,Meyers JA,etc.Blockade of TLR9 agonist-induced type I interferons promotes inflammatory cytokine IFN-gamma and IL-17 secretion by activated human PBMC.[J].2006,35(5).
- [8]Chang S,Fischer R,Kuchen S,etc.Identification and characterization of a human CD5+ pre-naive B cell population.[J].2009,182(7).
- [9]Yang P,Wang J,Yi J,etc.Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice[J].2008,9(2).
- [10]Hsieh,H.-J.,Wallace,D.J.,Oates,J.C.,etc.Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial[J].2010,62(1).
- [11]Zhong J,Ryel J,Recta V,etc.Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.[J].2008,58(8).
- [12]Niwa H,Matsushima Y,Satoh T.Stable form of galectin-9, a Tim-3 ligand, inhibits contact hypersensitivity and psoriatic reactions: a potent therapeutic tool for Th1- and/or Th17-mediated skin inflammation.[J].2009,132(2).
- [13]Gomez J,Lopez P,Prado C.Conserved anti-proliferative effect and poor inhibition of TNFalpha secretion by regulatory CD4+CD25+ T cells in patients with systemic lupus erythematosus.[J].2009,132(3).
- [14]Toshiharu Hayashi.Therapeutic Strategies for SLE Involving Cytokines: Mechanism-Oriented Therapies Especially IFN-gamma Targeting Gene Therapy[J].2010,2010(cytokines in systemi).
- [15]Kim SH,Shah K,Lee WW,etc.Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus.[J].2010,12(2).
- [16]Zhu C,Anderson AC,Schubart A,etc.The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity.[J].2005,6(12).
- [17]Barath S,Aleksza M,Tarr T,etc.Measurement of natural (CD4+CD25high) and inducible (CD4+IL-10+) regulatory T cells in patients with systemic lupus erythematosus.[J].2007,16(7).
- [18]Bettelli E,Grenningloh R,Ho IC,etc.Ets-1 is a negative regulator of Th17 differentiation.[J].2007,204(12).
- [19]Torgashina AV,Bykovskaia SN,Soloviev SK,etc.Reduced number and function of CD4+CD25highFoxP3+ regulatory T cells in patients with systemic lupus erythematosus.[J].2007,601(0).